Compare AMWL & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMWL | ORMP |
|---|---|---|
| Founded | 2006 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.6M | 170.3M |
| IPO Year | 2020 | 2010 |
| Metric | AMWL | ORMP |
|---|---|---|
| Price | $12.30 | $4.78 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $7.40 | N/A |
| AVG Volume (30 Days) | 83.0K | ★ 215.0K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | 57.06 | ★ 412.50 |
| EPS | N/A | ★ 2.76 |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.24 | N/A |
| P/E Ratio | ★ N/A | $1.80 |
| Revenue Growth | N/A | ★ 49.25 |
| 52 Week Low | $3.71 | $2.09 |
| 52 Week High | $14.19 | $5.47 |
| Indicator | AMWL | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 57.29 | 49.85 |
| Support Level | $8.25 | $3.91 |
| Resistance Level | $13.45 | $5.10 |
| Average True Range (ATR) | 0.68 | 0.24 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 67.80 | 7.59 |
American Well Corp is an enterprise platform and software company digitally enabling hybrid care by offering payers and health systems a technology-enabled care platform. The Amwell Platform, its cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings by enabling critical services like virtual primary care, urgent care, clinical partner programs, scheduling visits, etc. Additionally, the healthcare providers can use the platform to access familiar workflows for taking notes, prescribing, referencing clinical treatment guidelines, and other related activities. The firm also offers various paid services, including licensed clinical staffing, implementation support, workflow design, etc, to help clients execute their hybrid care strategies.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.